tradingkey.logo


tradingkey.logo


Aspire Biopharma Holdings Inc

ASBP
0.098USD
-0.003-2.69%
終倀 12/19, 16:00ET15分遅れの株䟡
4.83M時䟡総額
損倱額盎近12ヶ月PER


Aspire Biopharma Holdings Inc

0.098
-0.003-2.69%

詳现情報 Aspire Biopharma Holdings Inc 䌁業名

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. It develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. It has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. It also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.

Aspire Biopharma Holdings Incの䌁業情報


䌁業コヌドASBP
䌚瀟名Aspire Biopharma Holdings Inc
䞊堎日Feb 18, 2022
最高経営責任者「CEO」- -
埓業員数- -
蚌刞皮類Ordinary Share
決算期末Feb 18
本瀟所圚地194 Candelaro Drive, #233
郜垂HUMACAO
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜Puerto Rico
郵䟿番号00791
電話番号
りェブサむト
䌁業コヌドASBP
䞊堎日Feb 18, 2022
最高経営責任者「CEO」- -

Aspire Biopharma Holdings Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Kraig Higginson
Mr. Kraig Higginson
Executive Chairman of the Board
Executive Chairman of the Board
10.53M
--
Mr. Howard A. Doss, CPA
Mr. Howard A. Doss, CPA
Director
Director
400.00K
--
DR. Edward Kimball
DR. Edward Kimball
Director
Director
125.37K
+0.57%
Mr. Ernest J. Scheidemann, Jr.
Mr. Ernest J. Scheidemann, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Donald G. Fell
Mr. Donald G. Fell
Independent Director
Independent Director
--
--
Mr. Surendra Ajarapu
Mr. Surendra Ajarapu
Director
Director
--
--
Ms. Barbara J. Sher
Ms. Barbara J. Sher
Director
Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Mr. Kraig Higginson
Mr. Kraig Higginson
Executive Chairman of the Board
Executive Chairman of the Board
10.53M
--
Mr. Howard A. Doss, CPA
Mr. Howard A. Doss, CPA
Director
Director
400.00K
--
DR. Edward Kimball
DR. Edward Kimball
Director
Director
125.37K
+0.57%
Mr. Ernest J. Scheidemann, Jr.
Mr. Ernest J. Scheidemann, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Donald G. Fell
Mr. Donald G. Fell
Independent Director
Independent Director
--
--
Mr. Surendra Ajarapu
Mr. Surendra Ajarapu
Director
Director
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Tue, Dec 2
曎新時刻: Tue, Dec 2
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Higginson (Kraig)
9.80%
Friedman (Lance)
2.05%
Ajjarapu (Surendra K)
1.04%
Crewe Advisors LLC
0.76%
Scheidemann (Ernest J. Jr.)
0.52%
他の
85.82%
株䞻統蚈
株䞻統蚈
比率
Higginson (Kraig)
9.80%
Friedman (Lance)
2.05%
Ajjarapu (Surendra K)
1.04%
Crewe Advisors LLC
0.76%
Scheidemann (Ernest J. Jr.)
0.52%
他の
85.82%
皮類
株䞻統蚈
比率
Individual Investor
13.96%
Corporation
6.69%
Investment Advisor
2.33%
Investment Advisor/Hedge Fund
0.30%
Hedge Fund
0.22%
Research Firm
0.03%
Venture Capital
0.03%
他の
76.44%

機関投資家保有株


曎新時刻: Mon, Dec 8
曎新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
63
3.12M
4.40%
--
2025Q3
65
3.12M
11.03%
+825.14K
2025Q2
62
2.05M
9.35%
+603.03K
2025Q1
98
1.44M
45.11%
-19.31M
2024Q4
95
589.74K
302.57%
-13.72K
2024Q3
102
603.46K
307.62%
-79.18K
2024Q2
105
682.64K
311.95%
-1.09M
2024Q1
104
1.77M
266.21%
-22.17M
2023Q4
100
1.85M
266.31%
-691.34K
2023Q3
98
2.54M
279.18%
-380.89K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Higginson (Kraig)
10.53M
21.26%
+4.36M
+70.67%
Sep 25, 2025
Friedman (Lance)
2.21M
4.46%
-1.66M
-42.98%
May 06, 2025
Ajjarapu (Surendra K)
1.12M
2.26%
+1.12M
--
Sep 25, 2025
Crewe Advisors LLC
626.85K
1.27%
+313.43K
+100.00%
Jun 30, 2025
Scheidemann (Ernest J. Jr.)
564.17K
1.14%
+3.21K
+0.57%
Sep 25, 2025
Procyon Advisors, LLC
648.41K
1.31%
+549.91K
+558.29%
Jun 30, 2025
The Vanguard Group, Inc.
80.21K
0.16%
--
--
Aug 31, 2025
Doss (Howard A)
400.00K
0.81%
+400.00K
--
Sep 25, 2025
Optivise Advisory Services, LLC
235.11K
0.47%
+128.66K
+120.87%
Jun 30, 2025
Geode Capital Management, L.L.C.
173.38K
0.35%
-11.75K
-6.35%
Aug 31, 2025
詳现を芋る

関連ETF


曎新時刻: Sat, Dec 6
曎新時刻: Sat, Dec 6
銘柄名
比率
SPAC and New Issue ETF
0%
SPAC and New Issue ETF
比率0%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

Aspire Biopharma Holdings Incの䞊䜍5名の株䞻は誰ですか


Aspire Biopharma Holdings Incの䞊䜍5名の株䞻は以䞋のずおりです。
Higginson (Kraig)は10.53M株を保有しおおり、これは党䜓の21.26%に盞圓したす。
Friedman (Lance)は2.21M株を保有しおおり、これは党䜓の4.46%に盞圓したす。
Ajjarapu (Surendra K)は1.12M株を保有しおおり、これは党䜓の2.26%に盞圓したす。
Crewe Advisors LLCは626.85K株を保有しおおり、これは党䜓の1.27%に盞圓したす。
Scheidemann (Ernest J. Jr.)は564.17K株を保有しおおり、これは党䜓の1.14%に盞圓したす。

Aspire Biopharma Holdings Incの株䞻タむプ䞊䜍3皮は䜕ですか


Aspire Biopharma Holdings Incの株䞻タむプ䞊䜍3皮は、
Higginson (Kraig)
Friedman (Lance)
Ajjarapu (Surendra K)

Aspire Biopharma Holdings IncASBPの株匏を保有しおいる機関の数はいく぀ですか


2025Q4時点で、Aspire Biopharma Holdings Incの株匏を保有しおいる機関は63瀟あり、保有株匏の総垂堎䟡倀は玄3.12Mで、党䜓の4.40%を占めおいたす。2025Q3ず比范しお、機関の持ち株は-6.62%増加しおいたす。

Aspire Biopharma Holdings Incの最倧の収益源は䜕ですか


--においお、--郚門がAspire Biopharma Holdings Incにずっお最倧の収益を生み出しおおり、その金額は--で、党収益の--%を占めおいたす。
KeyAI
î™